You are here

Women's Imaging


Diffusion-weighted MRI (DWI) may soon command broader consideration than it’s been getting as a supplemental breast-screening tool. The modality not only finds many breast cancers that don’t show up on mammograms but also outperformed supplemental breast ultrasound in a study published online Oct. 28 in Clinical Imaging.

The U.S. Food and Drug Administration (FDA) issued an Oct. 27 reminder that thermography is not an acceptable substitute for mammography.

Screening mammography providers “on wheels” planning to serve medically underserved Latino communities would do well to first communicate with each community on perceptions of such services and, where needed, to offer education prior to rolling in.

Following screening mammography that turns up nothing, women with dense breast tissue are much more likely to pursue additional imaging with automated breast ultrasound (ABUS) when two things happen: their radiologists inform them of their tissue density and encourage them to consider the secondary exam because of it.

Image quality in mammography, thanks to concerns about radiation dose, faces a Goldilocks problem—where radiologists want to get the best image possible, while also minimizing risk to the patient. 


Recent Headlines

Automated breast ultrasound performs comparably to handheld

When women are recalled from screening mammography for additional imaging, they may soon be as likely to get scanned with automated ultrasound as with handheld, for European researchers have found similar performance between the two. 

Two-pronged approach may improve personalized breast cancer treatment

Researchers from multiple institutions have combined two methods of cancer detection to develop a new method in producing personalized breast cancer treatments. 

Cancer-center rads show the value of re-reading community breast exams

Reinterpretation of community breast studies by a specialized cancer center yielded a change in interpretation in some 28 percent of studies submitted for a second opinion during a four-month period, according to findings published online March 16 in the American Journal of Roentgenology.

Mercy Medical System first in New York to install clinical LumaGEM MBI system

Gamma Medica announced that New York’s first clinical LumaGEM Molecular Breast Imaging (MBI) system has been installed at Mercy Center, a member of Catholic Health Services of Long Island.

MRI breast screening: Not just for high-risk women

MRI breast screening is an effective supplement to traditional mammography, even for women with an average risk of breast cancer, according to a study published in Radiology.

Biennial breast-screening recommendation hasn’t moved the interval needle

The mammography screening debates have been raging ever since 2009, when the U.S. Preventive Services Task Force began recommending that most women get screened every other year rather than every year and start their screenings at 50 rather than 40. A new study shows that, among women routinely participating in mammography screening, the recommendation has not lengthened the average interval between exam dates. 

Affordable breast MRI protocol improving detection in women with dense breasts

Via Radiology, based in Seattle, is the first in the Pacific Northwest to offer a new type of MRI screening for breast cancer patients.

Government-run insurance marketplaces often fail to help women choose appropriate plans

Women seeking information about which plans cover which breast-health services in Affordable Care Act (ACA) marketplaces have been getting a lot of underinformed advice from customer-service reps. As a result, more than a few women have likely been buying plans that won’t meet their needs. 

Contralateral breast cancer a risk for women with dense tissue

Compared with breast-cancer patients who have nondense tissue, those with dense tissue are at significantly elevated risk of developing a tumor in the opposite breast. 

Breast imaging research team calls for raising the acceptable recall rate

Breast imaging practices that have screening recall rates of at least 12 percent but less than 14 percent are in the “sweet spot” for optimal detection of breast cancer. Practices that call back more than 14 percent of screening patients see little incremental benefit, while those that come in under 10 percent risk missing many cancers.